Historical zts News Stories
Zoetis OptiCell CHCM Upgrade Fuels Citi Buy $145Q2
Zoetis strengthened its point-of-care diagnostics with a CHCM upgrade to Vetscan OptiCell and received a Citi Buy initiation at $145, positioning diagnostics as a key near-term catalyst ahead of Q2 earnings.
Zoetis Boosts Genomics: Neogen Deal & BRD Rollout.
Zoetis recently completed a strategic acquisition of Neogen’s animal genomics business and has commercialized BRD genetic prediction metrics. With no fresh announcements in the past week, investor attention turns to integration, early adoption rates, and upcoming commercialization milestones that will influence ZTS performance.
Zoetis ZTS: BRD Genetics Boost Amid Guidance Trim.
Zoetis reported Q4 results and conservative 2026 guidance while launching commercial BRD genetic predictions for beef herds. The earnings and the new INHERIT BRD tools together reshape near-term sentiment but reinforce Zoetis's long-term strength in diagnostics and precision genetics.
Zoetis to Buy Neogen Genomics: ZTS Near-Term Up Q1
Zoetis announced a $160M purchase of Neogen’s animal genomics unit, expanding its precision animal health capabilities. The acquisition and a sharp spike in trading volume drove investor attention to ZTS; price moves were muted amid integration uncertainty. Key investor considerations include integration costs, timing for revenue synergy, and the opportunity to scale genotyping services across livestock and companion-animal customers.
Zoetis Q4 Beat, OA Antibodies and Vaccine Gains Q1
Zoetis reported stronger-than-expected Q4 2025 results and issued upbeat 2026 guidance, while regulatory approvals for long‑acting osteoarthritis antibodies and several animal vaccines added concrete near-term revenue drivers—developments that materially affect ZTS stock outlook.
Zoetis ZTS: $1.75B Notes AI Diagnostics Push
Zoetis (ZTS) reported modest Q4 results and set measured 2026 guidance while launching a $1.75B convertible note offering to support buybacks and strategic investments. The company is increasing its dividend and accelerating AI-enabled veterinary diagnostics and a deep therapeutic pipeline—factors that collectively shape near-term capital structure and longer-term growth prospects.
Zoetis ZTS: Durham Diagnostics Lab, AI Power Gains
Zoetis (ZTS) recently opened a major diagnostics and biodevices R&D facility in Durham and highlighted AI-driven discovery and a deep pipeline during an innovation webcast. These concrete investments strengthen Zoetis’s diagnostics capabilities and could accelerate product development timelines—important signals for investors following ZTS.